Top

Breast Cancer Research and Treatment

Published in:

Open Access 01-05-2017 | Epidemiology

Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology

Authors: EC Inwald, O Ortmann, M Koller, F Zeman, F Hofstädter, M Evert, G Brockhoff, M Klinkhammer-Schalke

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Abstract

Purpose

The 70-year threshold determines whether patients are eligible or not for the breast cancer screening program in Germany. It is not known whether this age threshold also influences the choice of adjuvant treatment and ultimate outcome.

Methods

3463 patients were analyzed from the clinical cancer registry Regensburg (Germany) with primary, non-metastatic invasive breast cancer diagnosed between 2000 and 2012. The distribution of tumor biological subtypes was evaluated in breast cancer patients both in those eligible for screening (ESG, 50–69 years) and those not eligible for screening (NESG, ≥70 years). Local and systemic therapies in different subtypes as well as overall survival (OS) were analyzed.

Results

2171 patients (62.7%) pertained to the ESG and 1292 patients (37.3%) referred to the NESG. The distribution of the common subtypes Luminal A, Luminal B, HER2-like, and Basal-like was comparable in both groups. Treatment varied considerably with less systemic therapies in all subtypes in patients in the NESG. Regarding local therapies, patients in the NESG also received less surgery and less radiotherapy. As to Luminal A patients, best OS was seen in patients receiving endocrine therapy (ET) (7-year OS of 95.6%) and CHT plus ET (7-year OS of 93.1%) in the ESG. In the NESG, best OS was seen in patients receiving CHT plus ET (7-year OS of 95.2%), whereas patients receiving only ET had a 7-year OS of 73.9%.

Conclusions

Despite similar tumor biology, elderly patients are undertreated regarding both systemic and local therapies compared to younger patients, leading to reduced OS.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. doi:10.3322/caac.21332 CrossRefPubMed

Tesarova P (2016) Specific aspects of breast cancer therapy of elderly women. Biomed Res Int. 2016:1381695 Epub 2016 Oct 11 CrossRefPubMedPubMedCentral

Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos K, Katalinic A, Langseth H, Larrañaga N, Rossi S, Siesling S, Minicozzi P; EUROCARE-5 Working Group. (2015) Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. Eur J Cancer. doi: 10.1016/j.ejca.2015.07.022. Epub ahead of print

Wallwiener CW, Hartkopf AD, Grabe E, Wallwiener M, Taran FA, Fehm T, Brucker SY, Krämer B (2016) Adjuvant chemotherapy in elderly patients with primary breast cancer: are women ≥65 undertreated? J Cancer Res Clin Oncol 142(8):1847–1853. doi:10.1007/s00432-016-2194-4 CrossRefPubMed

Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4):e148–e160. doi:10.1016/S1470-2045(11)70383-7 CrossRefPubMed

de Kruijf Esther M, Bastiaannet E, Ruberta F, de Craen Anton J M, Kuppen Peter J K, Smit Vincent T H B M, van de Velde Cornelis J H, Liefers GJ (2014) Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. Mol Oncol 8(5):1014–1025. doi:10.1016/j.molonc.2014.03.022 CrossRefPubMed

Diab SG, Elledge RM, Clark GM (2000) Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92(7):550–556CrossRefPubMed

Thomas GA, Leonard RCF (2009) Breast cancer in the elderly. Clin Oncol (Royal College of Radiologists (Great Britain)) 21(2):79–80. doi:10.1016/j.clon.2008.11.011 CrossRef

Sinn P, Aulmann S, Wirtz R, Schott S, Marme F, Varga Z, Lebeau A, Kreipe H, Schneeweiss A (2013) Multigene assays for classification, prognosis, and prediction in breast cancer: a critical review on the background and clinical utility. Geburtshilfe Frauenheilkd 73(9):932–940. doi:10.1055/s-0033-1350831 CrossRefPubMedPubMedCentral

10.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093 CrossRefPubMed

11.

Colombo P, Milanezi F, Weigelt B, Reis-Filho JS (2011) Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast cancer Res BCR 13(3):212. doi:10.1186/bcr2890 CrossRefPubMed

12.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.191367098 CrossRefPubMedPubMedCentral

13.

Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofstadter F, Gerstenhauer M, Brockhoff G, Ortmann O (2015) 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. Breast Cancer Res Treat 153(3):647–658. doi:10.1007/s10549-015-3572-3 CrossRefPubMedPubMedCentral

14.

Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139(2):539–552. doi:10.1007/s10549-013-2560-8 CrossRefPubMedPubMedCentral

15.

Inwald EC, Ortmann O, Zeman F, Koller M, Hofstadter F, Gerstenhauer M, Klinkhammer-Schalke M (2014) Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry. BioMed Res Int 2014:137304. doi:10.1155/2014/137304 CrossRefPubMedPubMedCentral

16.

Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofstadter F, Lindberg P, Gerstenhauer M, Schuler S, Treeck O, Ortmann O (2015) Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. J Cancer Res Clin Oncol 141(12):2229–2240. doi:10.1007/s00432-015-2025-z CrossRefPubMedPubMedCentral

17.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Gelber RD, Thurlimann B, Senn H (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral

18.

Kreienberg R, Albert U, Follmann M, Kopp IB, Kuhn T, Wockel A (2013) Interdisciplinary GoR level III guidelines for the diagnosis, therapy and follow-up care of breast cancer: short version—AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL—Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd 73(6):556–583. doi:10.1055/s-0032-1328689 CrossRefPubMedPubMedCentral

19.

Untch M, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Mobus V, Scheithauer H, Schneeweiss A, Thomssen C, Jackisch C, Beckmann MW, Blohmer J, Costa S, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Luck H, Maass N, Scharl A, Loibl S (2015) Primary therapy of patients with early breast cancer: evidence, controversies, consensus: opinions of German specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe und Frauenheilkunde 75(6):556. doi:10.1055/s-0035-1546120 CrossRefPubMedPubMedCentral

20.

Passage KJ, McCarthy NJ (2007) Critical review of the management of early-stage breast cancer in elderly women. Intern Med J 37(3):181–189. doi:10.1111/j.1445-5994.2007.01269.x CrossRefPubMed

21.

Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB (2014) Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist 19(10):1076–1083. doi:10.1634/theoncologist.2014-0184 CrossRefPubMedPubMedCentral

22.

Cappellani A, Di Vita M, Zanghi A, Cavallaro A, Piccolo G, Majorana M, Barbera G, Berretta M (2013) Prognostic factors in elderly patients with breast cancer. BMC Surg 13(Suppl 2):S2. doi:10.1186/1471-2482-13-S2-S2 CrossRefPubMedPubMedCentral

23.

Early Breast Cancer Trialists´ Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England) 365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0 CrossRef

24.

Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293(9):1073–1081. doi:10.1001/jama.293.9.1073 CrossRefPubMed

25.

Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065. doi:10.1056/NEJMoa0810266 CrossRefPubMedPubMedCentral

26.

Jolly TA, Williams GR, Bushan S, Pergolotti M, Nyrop KA, Jones EL, Muss HB (2016) Adjuvant treatment for older women with invasive breast cancer. Women’s health (London, England) 12(1):129–145; quiz 145-6. doi: 10.2217/whe.15.92

27.

Bastiaannet E, Liefers GJ, de Craen AJM, Kuppen PJK, van de Water W, Portielje JEA, van der Geest LGM, Janssen-Heijnen MLG, Dekkers OM, van de Velde CJH, Westendorp RGJ (2010) Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat 124(3):801–807. doi:10.1007/s10549-010-0898-8 CrossRefPubMed

28.

Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Kohne C, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (London, England) 382(9897):1021–1028. doi:10.1016/S0140-6736(13)61094-6 CrossRef

29.

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (London, England) 369(9555):29–36. doi:10.1016/S0140-6736(07)60028-2 CrossRef

30.

Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A (2013) Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 39(1):44–50. doi:10.1016/j.ctrv.2012.03.009 CrossRefPubMed

31.

Tsai H, Isaacs C, Fu AZ, Warren JL, Freedman AN, Barac A, Huang C, Potosky AL (2014) Risk of cardiovascular adverse events from trastuzumab (Herceptin((R))) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat 144(1):163–170. doi:10.1007/s10549-014-2836-7 CrossRefPubMedPubMedCentral

32.

Sawaki M, Mukai H, Tokudome N, Nakayama T, Taira N, Mizuno T, Yamamoto Y, Horio A, Watanabe T, Uemura Y, Ohashi Y (2012) Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Breast cancer (Tokyo, Japan) 19(3):253–258. doi:10.1007/s12282-011-0270-9 CrossRef

33.

Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su C, Yu S, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A (2008) Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19(6):1090–1096. doi:10.1093/annonc/mdn005 CrossRefPubMed

34.

Grumpelt A, Ignatov A, Tchaikovski SN, Burger E, Costa S, Eggemann H (2016) Tumor characteristics and therapy of elderly patients with breast cancer. J Cancer Res Clin Oncol 142(5):1109–1116. doi:10.1007/s00432-015-2111-2 CrossRefPubMed

35.

Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24(18):2757–2764. doi:10.1200/JCO.2005.03.6053 CrossRefPubMed

36.

Giordano SH, Duan Z, Kuo Y, Hortobagyi GN, Goodwin JS (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. Journal Clin Oncol 24(18):2750–2756. doi:10.1200/JCO.2005.02.3028 CrossRef

37.

Weggelaar I, Aben KK, Warle MC, Strobbe LJ, van Spronsen DJ (2011) Declined guideline adherence in older breast cancer patients: a population-based study in the Netherlands. Breast J 17(3):239–245. doi:10.1111/j.1524-4741.2011.01074.x CrossRefPubMed

38.

Rocco N, Rispoli C, Pagano G, Ascione S, Compagna R, Danzi M, Accurso A, Amato B (2013) Undertreatment of breast cancer in the elderly. BMC Surg 13(Suppl 2):S26. doi:10.1186/1471-2482-13-S2-S26 CrossRefPubMedPubMedCentral

39.

Louwman WJ, Janssen-Heijnen MLG, Houterman S, Voogd AC, van der Sangen M JC, Nieuwenhuijzen GAP, Coebergh J WW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. European journal of cancer (Oxford, England 1990) 41(5):779–785. doi:10.1016/j.ejca.2004.12.025 CrossRef

40.

Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M (2007) Non-standard management of breast cancer increases with age in the UK: a population based cohort of women or = 65 years. Br J Cancer 96(8):1197–1203. doi:10.1038/sj.bjc.6603709 CrossRefPubMedPubMedCentral

41.

Hancke K, Denkinger MD, Konig J, Kurzeder C, Wockel A, Herr D, Blettner M, Kreienberg R (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–753. doi:10.1093/annonc/mdp364 CrossRefPubMed

Title: Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology
Authors: EC Inwald
O Ortmann
M Koller
F Zeman
F Hofstädter
M Evert
G Brockhoff
M Klinkhammer-Schalke
Publication date: 01-05-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4151-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer

Oncologist and organizational factors associated with variation in breast cancer multigene testing

A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy

Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer